Experimental autoimmune encephalomyelitis (EAE) is an autoimmune inflammation of the central nervous system and is used as the experimental model of multiple sclerosis (MS). The exact mechanism behind the disease is still unknown, but interleukin (IL)-17 expressing T cells are thought to mediate the disease. Toll-like receptors (TLRs) are known to have a role in the innate immune response against pathogens, and several TLRs have also a role in the disease course of EAE. Here, we show that treatment with a herpes simplex virus type 1 vector expressing the Th2 cytokine IL-5 ameliorates EAE and decreases the numbers of infiltrating lymphocytes in the brain. The effect involves downregulation of TLR 2, 3 and 9 mRNA expression and upregulation of type I interferons (IFNs) in brains during onset of disease. The elevated expression of type I IFNs was also observed during recovery.
INTRODUCTION

Multiple sclerosis (MS) is a demyelinating autoimmune disease of the central nervous system (CNS), characterized by infiltration of inflammatory cells into the CNS. Experimental autoimmune encephalomyelitis (EAE)
, a common animal model for MS, can be induced by immunization with myelin-derived antigens in adjuvants [1] [2] [3] [4] [5] or by adoptive transfer of myelin-activated T cells. 6 Cytokines are an important part of the host's immune response against pathogens and an imbalance in the cytokine network has a role in the initiation of autoimmune diseases. 7, 8 CD4 + T helper 1 (Th1) cells, characterized by secretion of interferon (IFN)-g, tumor necrosis factor and interleukin-(IL-) 2, were until some years ago believed to be the essential T-cell population involved in the pathology and onset of the disease. Treatment with antibodies against IL-12, a cytokine that induces Th1 responses, was shown to ameliorate EAE. 9, 10 Later it was shown that IL-23 and not IL-12 is the crucial cytokine in CNS inflammation. [11] [12] [13] IL-23 also drives the expression of IL-17, 14 a relatively recently identified cytokine with a role in inflammation and autoimmune disease. [14] [15] [16] [17] The T cells producing IL-17 make a separate Th 17 T-cell population, distinct from Th1 and Th2. 15, 18 Both the CD4 + Th1 cells and Th 17 T cells are probably important during disease onset. Regulatory CD4 + CD25 + T cells (T-regs) are important in maintaining the balance between tolerance and immunity, 19 suppressing pathogenic autoreactive T cells. 20, 21 CD8 + T cells may also have a regulatory role in EAE. 22 Evidence suggests that Th2 type cytokines, such as IL-4 and IL-10 are associated with the recovery phase of EAE and also of MS, 23 whereas certain cytokines such as IFN-g, tumor necrosis factor-a and tumor necrosis factor-b have a disease-promoting role. 24 The Th1/Th2 paradigm in autoimmune disease has been targeted for potential treatments of EAE. Results have been contradicting but helpful in understanding the role of the different cytokines. Th2 cytokines have, for example, been used for therapy of EAE, either directly administered or expressed from viral vectors. Administration of IL-4 by viral vectors has shown beneficial effects in EAE recovery. [25] [26] [27] [28] Along with others, we have previously used intrathecally or intracranially delivered Th2 cytokine-expressing HSV vectors for treatment of EAE. [26] [27] [28] [29] [30] Still, mice lacking the IL-4 gene have shown variable susceptibility to EAE, depending on mouse strain. 31, 32 Studies with IL-10-deficient mice have, on the other hand, shown that IL-10 is critical in the regulation of EAE. 33 IL-5 is also a Th2 cytokine and induces maturation and differentiation of eosinophils. 34, 35 Treatments in use for MS, such as glatiramer acetate, seem to involve the upregulation of IL-5 together with IL-13. [36] [37] [38] Still, certain IL-5-deficient mice do develop EAE, which indicates that the role of IL-5 in the development of EAE is still controversial. 39 Important factors in innate immune response are the pathogenassociated pattern recognition molecules, such as toll-like receptors (TLRs). TLRs are important molecules also in the initiation of the adaptive immune responses. In all, 11 human TLRs and 13 mouse TLRs have been identified so far. Typical for all TLRs are that they are ligand-specific 40 and that they activate intracellular signaling pathways that lead to the induction of inflammatory cytokines, such as IFN-a, IL-6 and IL-12 (Th1 responses). Several groups have studied the role of TLRs in autoimmune disease. TLR agonists have been shown to induce autoimmune diseases, for example, EAE and diabetes. 41, 42 On the other hand, TLR stimulation can also suppress autoimmune pathogenesis, showing a more complex role for TLR in autoimmune diseases. 43, 44 Vectors based on herpes simplex virus type 1 (HSV-1) have several features making them a good candidate for gene therapy of CNS disease. HSV-1 is naturally neurotropic, thus after primary infection of epithelial cells, the virus is transported along nerves to the sensory ganglia, where it can establish a latent infection. 45, 46 In addition, the large DNA genome contains several non-essential genes, which can be removed or replaced by transgenes. The neurovirulence gene g 1 34.5 can also be removed from the vectors. 47, 48 HSV vectors can be administered into CNS by intracranial injection, intrathecally or through peripheral organs, such as the eye and nose. 49 Intranasal administration of wild-type HSV-1 yields an effective means of delivery in SJL/J mice. 50 We have previously studied the spread and replication of wild-type HSV-1 and vectors deleted of g 1 34.5 after corneal, intralabial and intranasal infection. We also found that the intranasal route was effective for delivery of HSV-1 and g 1 34.5-deletion viruses into the CNS. 51 As a beneficial role of both IL-5 and IL-10 has been indicated in EAE and MS, we wanted to investigate their therapeutic effect in SJL/J mice when expressed from HSV vectors. We have here studied the treatment with replicative HSV-1 vectors expressing IL-5 or IL-10 on EAE after peripheral administration and also studied the cytokine and TLR profiles during the treatments. We saw a significant decrease in disease score with the HSV-1 expressing IL-5, but not with IL-10-HSV. The IFN-b mRNA expression was upregulated in the CNS by the Th2 cytokine-expressing HSV vectors. We also observed a trend of decreasing IL-17 mRNA expression during the onset of disease after treatment with the cytokine-expressing HSV-1 vectors. TLR2, TLR3 and TLR9 expression were also modulated after administration of the replicative IL-5-HSV and they may be involved in the recovery of the animals. To our knowledge, this is the first study where IL-5 expressed from a viral vector has been used in gene therapy of EAE.
RESULTS
Replicative HSV-1 vector expressing IL-5 precludes EAE in SJL/J mice We studied the effect of intranasal administration of recombinant HSV-based vectors, expressing Th2 type cytokines, to the disease course of EAE in SJL/J mice. The experiment included four groups of mice, all induced for EAE: (1) no treatment, (2) infection with an HSV-1 deleted of the g 1 34.5 genes and expressing IL-10 (R8308), (3) infection with an HSV-1 deleted of the g 1 34.5 genes and expressing IL-5 (R8316) and (4) infection with an HSV-1 deleted of the g 1 34.5 genes but not expressing any cytokine (R3659). The mice were observed daily for disease grade. All untreated mice developed symptoms, showing that the induction of EAE was successful. The time of disease onset did not differ significantly between the groups. Most mice developed symptoms starting on days 11-12 post induction (Table 1) . The EAE disease peak also occurred approximately at the same time for all groups, but disease scores were highest in the untreated group and a significant decrease (Po0.05) could be seen in the mice infected with R8316 (IL-5) after day 15 post induction ( Figure 1 ). There was no EAE mortality, either, in the R8316 (IL-5) treatment group (Table 1) . The EAE cumulative index was lowest in the HSV-1-IL-5-treated group (Table 1) . Since IL-10 has a role during the recovery phase of EAE, we also studied the effect of an HSV-1 expressing IL-10. Treatment with R8308 (IL-10) caused no significant alleviation of EAE in comparison with untreated mice. The control virus R3659 also alleviated the EAE scores during the recovery phase starting from day 18 (Figure 1) , indicating a beneficial effect of the backbone HSV vector during the late phase of the EAE.
Microscopical analysis of brain samples
Hematoxylin-eosin-stained brain paraffin sections were analyzed for amount of lymphocyte infiltrates and pathological changes typical for EAE (Figures 2 and 3) . At day 14 post induction, a strong inflammation could be seen in the brain of untreated EAE mice, with numerous infiltrating lymphocytes. Also in the HSV-treated groups inflammation could be seen during the acute disease ( Figure 2) . By day 21, the inflammation had decreased in the brains and there was a significant Infiltrates were composed of leukocytes (CD45), including CD4 + and CD8 + T-lymphocytes ( Figure 3 ). There was a trend of lower CD4 + to CD8 + ratio in HSV-treated mice. Antigen-presenting cells (F4/80) were also found in the infiltrates. There was, as well, a trend toward fewer F4/80-positive cells in HSV-treated mice than in untreated EAE ( Figure 3 ). The IL-5-HSV treatment was not associated with significant increase in eosinophilic leukocytes in the CNS (Supplementary Figure 1) . In spinal cords of mice recovered from severe disease (grade 3), inflammatory infiltrates were still found at day 21 post induction in both untreated and treated EAE mice. However, less infiltrates were seen in the IL-5-HSV treatment group ( Figure 4 ). There were no significant differences between the treatment and no treatment groups in infiltrate composition, although there was a trend toward higher proportion of CD8 + cells in HSV-treated groups.
Viral transcripts in the nervous system
As the viruses were administered intranasally, we studied the trigeminal ganglion (TG) samples for the viral DNA (PCR for the HSV-1 gD target). The majority of all TGs from infected animals were positive for HSV-1 DNA (Supplementary Table 2A ). In addition, we studied the TG with a transgene-specific PCR. IL-5 transgene copies could be found in a few TG samples from R8316-infected mice at day 10 post induction (day 4 post infection) and in almost all TGs later in the disease (Supplementary Table 2B ). TG samples from R8308 (IL-10)-infected mice were positive for the IL-10 transgene. As expected, TGs of mice infected with R3659 were negative for the tested transgenes.
TLR and type I IFN expression in nervous system of SJL/J mice with EAE We studied the effect on the TLR expression in the CNS of the replicative HSV-1 vectors expressing IL-5 or IL-10 and the R3659. The mRNA expression of TLR2, TLR3 and TLR9 were analyzed from brain samples. In addition, expression of MyD88, and the expression of type 1 IFNs IFN-a4, IFN-a6 and IFN-b were analyzed.
All of the studied TLRs were significantly (Po0.05) downregulated in brains of the mice infected with R8316 (IL-5) during the onset of the EAE disease as compared with untreated mice ( Figure 5 ). Infection with R8308 (IL-10) showed a similar tendency. Infection with R3659 upregulated all studied TLRs throughout the disease. Significant differences were found between the Th2 cytokine-expressing vectors and R3659. R8316 (IL-5) slightly upregulated the mRNA expression of TLR2, TLR9 and MyD88 at day 14 post induction in comparison with untreated EAE, but not to the extent that R3659 did. Treatment with R8308 (IL-10) showed a similar tendency, but the upregulation was not significant.
The type 1 IFN mRNA expression followed a common pattern ( Figure 5 ). R8316 (IL-5) infection significantly (Po0.05) upregulated the IFN-a4, IFN-a6 and IFN-b mRNA expression at day 10 and day 21 post EAE induction in brains. R8308 (IL-10) infection downregulated the type 1 IFN mRNA expression during day 10, but thereafter significantly upregulated the mRNA expression on both day 14 and day 21. Also the R3659 virus upregulated the IFN responses at day 14. Still, both R8308 (IL-10) and R8316 (IL-5) showed higher type I IFN mRNA expression than R3659 during recovery.
HSV expressing IL-5 or IL-10 modulates the cytokine response in the nervous system Expression of several cytokines was studied from brain and TG samples, including IL-4, IL-5, IL-10, IFN-g, IL-17, IL-23, IL-12p35 and IL-12p40 mRNA.
In brains of SJL/J mice induced for EAE and treated with R8316 (IL-5) or with R8308 (IL-10), we could see a trend of a downregulation of the pro-inflammatory cytokine IL-17 during onset of disease (day 10) (Figure 6 ). A significant reduction was seen in IL-23 mRNA expression after R3659 infection on day 10 and 21 in comparison with both untreated EAE and treatment with the Th2 cytokine-expressing vectors. R8308 (IL-10) downregulated IL-12p40 during the acute EAE phase (day 14). Both R8308 and R8316 showed lower IL-12p40 mRNA expression than R3659, which upregulated IL-12p40 throughout the disease. R8316 downregulated IL-12p35 during recovery (day 21). No significant changes were seen in the IFN-g mRNA expression in comparison with untreated mice, although the Th2 cytokine-expressing HSV vectors had lower IFN-g levels than R3659. The HSV-1s expressing IL-5 or IL-10 did not increase the IL-5 expression in the brains at day 4 post infection, but later during the treatment IL-5 was observed ( Figure 6 ). The virus R3659 upregulated IL-5 on day 14 and day 21. The IL-10 mRNA expression was upregulated after R8316 (IL-5) at day 14 and day 21 and at day 21 after R8308 (IL-10)-treatment. Both Th2 cytokineexpressing vectors induced higher IL-10 mRNA expression than R3659 at the recovery phase.
The phenomena in the TG may affect the outcome of EAE, providing a contact of the immune system with HSV vectors expressing cytokines. In the TG, we found a significant upregulation of the IL-5 expression in SJL/EAE mice infected with R8316 (IL-5) at day 14 and day 21 post induction (day 8 and 15 post infection), compared with both untreated EAE mice and mice infected with R3659 ( Figure 7 ). Mice infected with the IL-5 virus also showed a significant upregulation of the IL-10 mRNA expression in the TG at day 14, but a downregulation during the recovery phase ( Figure 7 ). This indicates that the R8316 (IL-5) induced a Th2-type response in the TG. A temporary upregulation of IL-17 was seen in TG, but not in brain, at day 14 post EAE induction in mice infected with R8316 (IL-5). R8308 (IL-10) also induced similar patterns but not a significant response. Neither of the cytokine-expressing viruses significantly affected the IL-12p40 or IFNg mRNA expression in the TG. R3659 upregulated the IL-12p40 expression also in TGs. Only single TG samples were positive for IL-12p35 or IL-4 and therefore no significant changes were seen (data not shown). HSV-1 expressing IL-5 ameliorates EAE M Nygårdas et al
DISCUSSION
In this study, we found that an HSV-1 vector expressing IL-5 significantly ameliorates EAE. We observed marked improvement of the disease score, the cumulative disease index and the EAE mortality rate in the animals treated with the virus R8316 (IL-5). The effect of the HSV vector involves an upregulation of the type 1 IFN response in the CNS, especially IFN-b. When treating the mice with the control virus R3659, we also saw a reduction in EAE scores during the late phase of EAE, as expected based on earlier reports. 28, 29 Treatments with all of the HSV-1 vectors used in this study showed a significantly lower cumulative disease index than for the untreated EAE mice. This confirms earlier findings that replicative g 1 34.5-negative HSV as such also have beneficial effects on EAE. No clear differences in CNS inflammatory infiltrate composition were seen between the different treatment groups, but there was a tendency toward a higher proportion of CD8 + cells in the CNS of HSV-treated mice. This is in accordance with the proposed regulatory role of CD8 + cells in EAE. 22 Eosinophilic leukocytes were observed in infiltrates of R8316 (IL-5)-treated EAE mice, but were also observed in the other EAE groups in accordance with observations in other EAE models 52 (Supplementary Figure 1) .
Overall, contradicting views exists regarding the roles of different cytokines and their effects on the disease course of EAE and MS. Several studies have indicated the importance of IFN-b in the recovery from EAE. Mice depleted of the type I IFN receptor (IFNAR) 53, 54 or negative for the IFN-b gene showed exacerbated EAE. 55 Guo et al. 54 suggested that the type I IFNs constrain IL-17, whereas a study by Prinz et al. 53 shows that IFN-b suppresses chemokine expression and upregulation of major histocompatibility complex class II molecules on macrophages and microglia, as also discussed by Axtell and HSV 56 Studies have also shown that type 1 IFNs enhance production of IL-4 and IL-10 57-59 and diminish the production of the pro-inflammatory Th1 cytokines IFN-g and tumor necrosis factor-a in MS. 60 In this study, we saw a significantly higher upregulation in IFN-b mRNA expression with R8316 (IL-5) in comparison with both R3659 and untreated mice.
Touil et al. 44 have shown that TLR3 stimulation with the TLR3 agonist polyinosinic:polycytidylic acid (double-stranded RNA analog) suppressed demyelization in SJL/J mice with EAE by inducing IFN-b. The IFN-b upregulation that we obtained is most likely dependent on signaling from other sensors than TLR3 since we obtained a decrease in TLR3 mRNA expression after treatment with HSV-1 expressing IL-5 or IL-10. In addition, our unpublished observations indicate that TLR3 is downregulated in spleen cells treated with the Th2 cytokines IL-4, IL-5 or IL-10 in combination with ConA stimulation. IL-5 also downregulated the TLR3 expression during polyinosinic:polycytidylic acid stimulation (data not shown). Mueller et al. 61 have also shown that the Th2 cytokines IL-4 and IL-13 downregulated TLR3 and TLR4, while IFN-g enhanced their expression in human intestinal epithelial cells. The group also studied the effect of IL-5, but did not see the same effect as with IL-4 and IL-13, probably due to the lack of IL-5 receptor in the used cell line. The TLR3 changes that we saw might therefore be a response to the expressed Th2 cytokines. This is also supported by the fact that there were significant differences in TLR3 mRNA expression between the backbone virus R3659 and the Th2 cytokine-expressing HSV vectors.
The treatment with HSV vectors expressing IL-5 or IL-10 in SJL/J mice with EAE also influences other TLR responses, as we, in addition, 
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believed to be crucial for the induction of EAE since MyD88 À/À mice are resistant to EAE. 62 T cells from MyD88-negative mice do not express IL-17. 63 This is accordance with our findings that MyD88 is downregulated early during the treatment with HSV vectors expressing Th2 cytokines, and thus might explain why these HSV vectors ameliorated the EAE disease course.
IL-10 has been presented as a critical Th2 cytokine in recovery and regulation of EAE. 23, 33 We therefore also studied the effect of IL-10 expressed from a HSV-1 vector. We did not see a significant effect on the EAE disease course when the IL-10-HSV was administered intranasally as we did for the IL-5-expressing HSV. This is in accordance with an previous study of ours, where IL-10, when expressed from an HSV-1 vector, did not have a significant alleviating effect on the disease course. 29 Still, both HSV-1 vectors expressing Th2 cytokines had similar effect on many of the studied cytokines. We have earlier observed upregulation of IL-23 in nervous system of mice infected with wild-type HSV-1. 64 However, the g 1 34.5 deletion viruses used in this study did not upregulate IL-23 in the TG, except for R8316 at day 21. R3659 even downregulated IL-23 in the brain during onset of disease. In addition, R3659 upregulated IL-12p40 both in brains and TGs. The IL-10 virus also affected IL-12p40 in the brain, whereas the IL-5 virus downregulated IL-12p35. This indicates that IL-10 and IL-5 might limit the inflammation through downregulation of these cytokines. Studies by Becher and Cua [11] [12] [13] has shown that IL-23 and IL-12 are involved in the inflammation in EAE, although IL-17 is now believed to be the main disease-promoting cytokine in CNS inflammation. 65 Although it is known that HSV infection activates IFN-g expression, 66 ,67 no significant changes were seen in mRNA expression of IFN-g in the brain or in the TG with our g 1 34.5 deletion viruses. There was, however, a trend of decreased IFN-g expression after treatment with R8316 (IL-5) and a significant lower IFN-g expression was seen for the IL-5-HSV and the IL-10-HSV than for R3659.
Treatment with R8316 (IL-5) upregulated the Th2 cytokine IL-10, both in brains and TG, during the acute phase. Both cytokineexpressing HSV vectors upregulated IL-10 mRNA expression during recovery in brains, also in comparison with R3659. We also saw an upregulation of the IL-5 expression in the TG after R8316 (IL-5) infection, indicating that the virus expressed IL-5 properly. This was further supported by our results from a transgene PCR, where transgene transcripts were found in most TGs (Supplementary  Table 2 ). Our results also indicate that the empty vector R3659 and the cytokine-expressing HSV vectors cause different changes in cytokine profiles and TLR expression.
The changes observed in the CNS and TG are not similar in all respects. The cytokine profiles and changes observed in the CNS during treatment are likely influenced by the pathogenic and repair processes occurring in EAE, meanwhile the cytokine changes in the TG are likely less affected by the EAE pathogenesis, reflecting more directly the effects of the HSV vectors and of the innate antiviral responses. The vectors also reach the CNS later than they reach the TG.
The cytokine IL-5 has not been widely studied in MS or in EAE. Our study indicates that IL-5 has a role in the control of the disease, and might involve regulation of IL-17 and IFN-b. The HSV vectors expressing IL-5 or IL-10 also affected TLR responses, which we believe are also important factors in the pathogenesis of the disease. The therapeutic outcome of R8316 is likely a combination of the beneficial effect of the HSV-1 backbone and the IL-5. As observed earlier, R3659 is able to induce Th2 responses by itself, explaining the effects of the HSV backbone. 28, 51, 68 This study also supports previous studies, 26, 27, 29, 69 indicating that HSV vectors are good candidates for gene therapy of CNS diseases. Still, it is important to study the safety of these vectors and also optimize the expression efficiency in the target tissue. 
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MATERIALS AND METHODS
Viral vectors
The vectors used in this study are based on the HSV-1 virus strain F, and are derived from the virus R3659. 70 The virus R3659 carries the thymidine kinase gene under the a27 gene promoter in the deletion of g 1 34.5 locus. As a consequence, the viruses do not replicate in nondividing cells such as neurons. Both the R8308 (IL-10) and the R8316 (IL-5) virus have an insertion of the mouse Th2 cytokine in the deleted regions of the g 1 34.5 gene. The viruses were thymidine kinase-positive. The virus R3659 and genomic structure of the cytokine-expressing HSV vectors have been described before. 29, 68, 71 Cytokine expression from the HSV vectors expressing IL-10 and IL-5 was tested from supernatants with EIA (eBioscience, San Diego, CA, USA). Shortly, CSM rat neuronal cells were infected with R8308 and R8316 and supernatants were collected. IL-10 was produced at the level of 850 pg ml -1 at 24 h after R8308 infection. The R8316 virus produced 5.1 pg ml -1 of IL-5 at 24 h post infection. Both viruses were a kind gift from Dr Bernard Roizman, the University of Chicago, Chicago, IL, USA. 
Treatment of EAE
In all, 1Â10 7 p.f.u. of HSV-1 viral vectors R3659, R8308 (IL-10) and R8316 (IL-5) were diluted in 10 ml of phosphate-buffered saline. In total, 5 ml virus dilution was administered in anesthetized mice in each of the nostrils on day 6 post EAE induction (day 0 of infection). Control EAE mice were left untreated. All groups consisted of 15-20 mice.
Dissection and processing of tissues
Five mice from each group were killed under CO 2 anesthesia at 10, 14 and 21 days after EAE induction. Mice were perfused with phosphate-buffered saline via the left chamber of the heart after lethal CO 2 anesthesia. Samples were taken from the midbrain level for virus culture and PCR. The rest of the brain samples were fixed in 4% phosphate-buffered formaldehyde for microscopy. Spinal cords were taken on day 21 and fixed in 4% phosphate-buffered formaldehyde. In all, 4 mm paraffin sections were made and transferred onto glass microscope slides. Samples from the TG were taken for viral culture and for DNA and RNA extraction.
Neuropathological examinations
Formaldehyde-fixed 4 mm paraffin brain and spinal cord sections were stained with hematoxylin and eosin. The specialist of neuropathology scored the severity of inflammatory infiltrates in the CNS. The scoring was: 0, no infiltration; 1, perivascular infiltration; 2, perivascular inflammatory cuffs; and 3, inflammation of the brain substance.
Immunohistochemistry was performed to analyze the cell composition of infiltrates in brains and spinal cords. Fixed samples were deparaffinized and rehydrated by incubating slides overnight at +60 1C and washed in Xylene (2Â5 min), and subsequently in 100%, 96% and 70% ethanol (2Â2 min each).
Heat-induced epitope retrieval was done in sodium citrate buffer, pH 6.0 (10 mM). Samples were stained for leukocytes (CD45, AbDSerotec, Oxford, UK, 1:2000), T lymphocytes (CD4, Abcam, Cambridge, UK, 1:1000; CD8, AbDSerotec, 1:100), and antigen-presenting cells (F4/80, AbDSerotec 1:80). Sections were incubated with the primary antibody overnight at +4 1C. Primary antibodies were detected using Vectastain ABC kit (Vector Laboratories, Burlingame, CA, USA) according to the manufacturer's instructions and stained with diaminobenzidine. All antibodies were diluted in Tris-buffered saline containing 1% bovine serum albumin.
Viral culture
Brain and TG samples were homogenized by shaking the samples in tubes with glass beads (Assistant Ø 1 mm, VWR International Oy, Espoo, Finland) at +4 1C for 2Â45 s with Mikro-dismembrator II device (Medical Braun Ab, Espoo, Finland). Thereafter the samples were centrifuged for 30 s. The TG samples were diluted 1:2 and the brain samples 1:10 in RPMI medium containing 0.1% bovine serum albumin before overlaying cells in six-well culture dishes with 0.5 ml virus dilution. Cells were incubated for 1-2 h at room temperature before changing the medium to Eagle's minimal essential medium containing 7% fetal calf serum and 20 mg ml -1 human immunoglobulin G. Cells were then incubated for 3 days at 37 1C and 5% CO 2 , fixed in methanol for 10 min and stained with 0.1% crystal violet in 2% ethanol. Samples taken on day 21 post induction were incubated in culture medium for 5 days before homogenization and plaque titration to reactivate the possible latent virus. 51, 72 DNA and RNA extraction DNA was extracted from brain and TG samples with EZNA tissue extraction kit (OMEGA, Bio-tek, Norcross, GA, USA) according to the manufacturer's manual. TG samples were processed from viral culture tubes.
RNA was extracted with Trizol Reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer's instructions. In all, 1 ml of Trizol was used for brain samples and 500 ml was used for TG samples. The RNA was diluted in 20 ml of water treated with diethylpyrocarbonate. Samples were then stored at À70 1C until complementary DNA (cDNA) transcription.
Reverse transcription
RNA was transcribed into cDNA as follows: 0.023 U pd(T) 12À18 (0.7 ml of 33 U ml -1 ) (Amersham Biosciences/GE Healthcare Bio Science, Pittsburgh, PA, USA) and 13.5 ml diethylpyrocarbonate-water were mixed and 5 ml RNA sample was added. The sample mixture was incubated at 70 1C for 5 min and then put on ice. Moloney murine leukemia virus RT 5Âbuffer, 5 mM dNTP, moloney murine leukemia virus reverse transcriptase Rnase H Minus enzyme (40 units) and Rnase inhibitor (8 units) , all from Promega (Madison, WI, USA) was then mixed in a PCR clean room and 5.7 ml mixture was added to the samples. The reverse transcriptase-reaction was carried out in PerkinElmer PCR machine (Waltham, MA, USA) under the following conditions; at +37 1C for 60 min followed by +90 1C for 5 min whereafter the samples were cooled to +4 1C. The cDNA was stored at À70 1C and used for quantitative real-time PCR.
Quantitation of HSV-1 gD gene, cytokine and TLR cDNA with real-time PCR Quantitative real-time PCR was performed with Rotor-Gene 6000 real-time instrument (Corbett Research, Mortlake, Victoria, Australia). Each reaction was carried out in a total volume of 20 ml containing 10 ml Quantitect SybrGreen PCR enzyme buffer mixture (Qiagen, Hilden, Germany), 10-20 pmol of each primer, 7 ml water and 2 ml cDNA samples. The amount of viral genome in the samples was studied by quantifying HSV-1 gD gene target. 64 This PCR mixture contained 10 ml SybrGreen, 3.75 pmol of each primer, 6 ml PCR-grade water and 4 ml DNA. The enzyme mixture was pipetted in a separate PCR clean room, where no PCR products were handled. The reaction was carried out using the following conditions: initial denaturation at 95 1C for 15 
Statistical analysis
Clinical disease scores were compared for the statistically significant difference between mouse groups and different timepoints. Cytokine and TLR mRNA expression after viral infection in SJL/J mice with EAE were compared with uninfected EAE mice. In addition, changes in mRNA expression were calculated between R3659 (backbone virus) and Th2-expressing HSV vectors. We used Statview software (Abacus Concepts, Berkeley, CA, USA) to calculate the Mann-Whitney U-test results.
